{"database": "lobbying", "table": "lobbying_activities", "rows": [[1917850, "676a23d0-5f30-4f91-b1ad-1edd18fdee0e", "Q4", "CHAMBER HILL STRATEGIES", 400645947, "AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL)", 2016, "fourth_quarter", "PHA", "Implementation issues related to P.L. 113-54, the Drug Quality and Security Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2017-01-18T13:18:10-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1917850"], "units": {}, "query_ms": 1.5690249856561422, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}